The Mitochondria in Diabetic Heart Failure: From Pathogenesis to Therapeutic Promise

Antioxidants and Redox Signaling

Volumn 22, Issue 17, 2015, Pages 1515-1526

  Schilling, Joel D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; GLUTATHIONE; INTERLEUKIN 1; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCOUPLING PROTEIN;

CITRIC ACID CYCLE; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HEART FAILURE; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID OXIDATION; LIPID STORAGE; LIPID TRANSPORT; LIPOTOXICITY; METABOLIC STRESS; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; METABOLISM; PATHOLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETIC CARDIOMYOPATHIES; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART;

EID: 84930665631     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6294     Document Type: Review

References (109)

1. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, Chang Z, Tripathy D, Jani R, Molina-Carrion M, Monroy A, Folli F, Van Remmen H, and DeFronzo RA. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab 295: E678-E685, 2008.
2. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, and Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19: 1088-1095, 2005.
3. Aguilar D, Deswal A, Ramasubbu K, Mann DL, and Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 105: 373-377, 2010.
4. Aliciguzel Y, Ozen I, Aslan M, and Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142: 172-177, 2003.
5. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, and Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 54: 1891-1898, 2009.
6. Angin Y, Steinbusch LK, Simons PJ, Greulich S, Hoebers NT, Douma K, van Zandvoort MA, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JF, and Luiken JJ. CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem J 448: 43-53, 2012.
7. Aydemir-Koksoy A, Bilginoglu A, Sariahmetoglu M, Schulz R, and Turan B. Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress. J Nutr Biochem 21: 827-833, 2010.
8. Batenburg JJ and Olson MS. Regulation of pyruvate dehydrogenase by fatty acid in isolated rat liver mitochondria. J Biol Chem 251: 1364-1370, 1976.
9. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, and Abel ED. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109: 629-639, 2002.
10. Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, Welty TK, Lee ET, Fabsitz RR, and Howard BV. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 87: 1260-1265, 2001.
11. Bene J, Marton M, Mohas M, Bagosi Z, Bujtor Z, Oroszlan T, Gasztonyi B, Wittmann I, and Melegh B. Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome. Ann Nutr Metab 62: 80-85, 2013.
12. Bessi VL, Labbe SM, Huynh DN, Menard L, Jossart C, Febbraio M, Guerin B, Bentourkia M, Lecomte R, Carpentier AC, Ong H, and Marleau S. EP 80317, a selective CD36 ligand, shows cardioprotective effects against postischaemic myocardial damage in mice. Cardiovasc Res 96: 99-108, 2012.
13. Boudina S and Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21: 250-258, 2006.
14. Boudina S, Han YH, Pei S, Tidwell TJ, Henrie B, Tuinei J, Olsen C, Sena S, and Abel ED. UCP3 regulates cardiac efficiency and mitochondrial coupling in high fat-fed mice but not in leptin-deficient mice. Diabetes 61: 3260-3269, 2012.
15. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, and Abel ED. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457-2466, 2007.
16. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR, Jr., Macdonald JA, Lees-Miller JP, Roach D, Semeniuk LM, and Duff HJ. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol 98: 462-472, 2013.
17. Bugger H and Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57: 660-671, 2014.
18. Canto C and Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105, 2009.
19. Cascio G, Schiera G, and Di Liegro I. Dietary fatty acids in metabolic syndrome, diabetes and cardiovascular diseases. Curr Diabetes Rev 8: 2-17, 2012.
20. Chacko BK, Reily C, Srivastava A, Johnson MS, Ye Y, Ulasova E, Agarwal A, Zinn KR, Murphy MP, Kalyanaraman B, and Darley-Usmar V. Prevention of diabetic nephropathy in Ins2(+/)(-)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J 432: 9-19, 2010.
21. Daffu G, del Pozo CH, O'Shea KM, Ananthakrishnan R, Ramasamy R, and Schmidt AM. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci 14: 19891-19910, 2013.
22. Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, and Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail 20: 304-309, 2014.
23. Davaapil H, Tsuchiya Y, and Gout I. Signalling functions of coenzyme A and its derivatives in mammalian cells. Biochem Soc Trans 42: 1056-1062, 2014.
24. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, Kitzman DW, Hopkins PN, Arnett DK, and Devereux RB. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 20: 323-331, 2002.
25. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, and Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101: 2271-2276, 2000.
26. Dhalla NS, Elimban V, and Rupp H. Paradoxical role of lipid metabolism in heart function and dysfunction. Mol Cell Biochem 116: 3-9, 1992.
27. Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, and Kelly DP. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 60: 339-343, 1999.
28. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, and Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139, 2009.
29. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, and Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation 121: 426-435, 2010.
30. Duncan JG, Fong JL, Medeiros DM, Finck BN, and Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115: 909-917, 2007.
31. El Messaoudi S, Rongen GA, and Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 15: 314, 2013.
32. Estep JD and Aguilar D. Diabetes and heart failure in the post-myocardial infarction patient. Curr Heart Fail Rep 3: 164-169, 2006.
33. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, and Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335: 497, 2007.
34. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100: 1226-1231, 2003.
35. Finck BN and Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622, 2006.
36. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, and Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002.
37. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, and Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 119: 591-599, 2006.
38. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, and Anversa P. Myocardial cell death in human diabetes. Circ Res 87: 1123-1132, 2000.
39. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, and Steinberg GR. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 19: 1649-1654, 2013.
40. Galderisi M, Anderson KM, Wilson PW, and Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68: 85-89, 1991.
41. Gerdts E, Okin PM, Omvik P, Wachtell K, Dahlof B, Hildebrandt P, Nieminen MS, and Devereux RB. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis 19: 306-312, 2009.
42. Gross O, Thomas CJ, Guarda G, and Tschopp J. The inflammasome: an integrated view. Immunol Rev 243: 136-151, 2011.
43. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, and Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104: 403-411, 2009.
44. Herlitz J, Malmberg K, Karlson BW, Ryden L, and Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand 224: 31-38, 1988.
45. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, and Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47: 598-604, 2006.
46. Huang X, Vaag A, Hansson M, and Groop L. Down-regulation of insulin receptor substrates (IRS)-1 and IRS-2 and Src homologous and collagen-like protein Shc gene expression by insulin in skeletal muscle is not associated with insulin resistance or type 2 diabetes. J Clin Endocrinol Metab 87: 255-259, 2002.
47. Ido Y. Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal 9: 931-942, 2007.
48. Ko HJ, Zhang Z, Jung DY, Jun JY, Ma Z, Jones KE, Chan SY, and Kim JK. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMPactivated protein kinase in the heart. Diabetes 58: 2536-2546, 2009.
49. Kobayashi S and Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochim Biophys Acta 1852: 252-261, 2015.
50. Kouvaras G, Cokkinos D, and Spyropoulou M. Increased mortality of diabetics after acute myocardial infarction attributed to diffusely impaired left ventricular performance as assessed by echocardiography. Jpn Heart J 29: 1-9, 1988.
51. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, and Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7: 45-56, 2008.
52. Kuramoto K, Okamura T, Yamaguchi T, Nakamura TY, Wakabayashi S, Morinaga H, Nomura M, Yanase T, Otsu K, Usuda N, Matsumura S, Inoue K, Fushiki T, Kojima Y, Hashimoto T, Sakai F, Hirose F, and Osumi T. Perilipin 5, a lipid droplet-binding protein, protects heart from oxidative burden by sequestering fatty acid from excessive oxidation. J Biol Chem 287: 23852-23863, 2012.
53. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyorala K, and Penttila I. Serum lipids and lipoproteins in middleaged non-insulin-dependent diabetics. Atherosclerosis 56: 271-281, 1985.
54. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, and Leite-Moreira AF. METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design: MET-DIME trial. Cardiovasc Drugs Ther 28: 191-196, 2014.
55. LaNoue KF, Bryla J, and Williamson JR. Feedback interactions in the control of citric acid cycle activity in rat heart mitochondria. J Biol Chem 247: 667-679, 1972.
56. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, and Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62: 194-204, 2013.
57. Li CJ, Lv L, Li H, and Yu DM. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 11: 73, 2012.
58. Lim S, Rashid MA, Jang M, Kim Y, Won H, Lee J, Woo JT, Kim YS, Murphy MP, Ali L, Ha J, and Kim SS. Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. Cell Physiol Biochem 28: 873-886, 2011.
59. Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, Davila-Roman VG, Stein RI, Dorn Ii GW, Gropler RJ, Waggoner AD, and Peterson LR. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity (Silver Spring) 19: 1804-1812, 2011.
60. Lindman BR, Arnold SV, Madrazo JA, Zajarias A, Johnson SN, Perez JE, and Mann DL. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circ Heart Fail 4: 286-292, 2011.
61. Lindman BR, Davila-Roman VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de Las Fuentes L, Joseph SM, Vader J, Hernandez AF, and Redfield MM. Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes: A RELAX Trial Ancillary Study. J Am Coll Cardiol 64: 541-549, 2014.
62. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV, Jr., Ory DS, and Schaffer JE. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100: 3077-3082, 2003.
63. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schaffer JE, Yu YH, and Goldberg IJ. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 284: 36312-36323, 2009.
64. Liu L, Yu S, Khan RS, Homma S, Schulze PC, Blaner WS, Yin Y, and Goldberg IJ. Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPARgamma transgenic mice. J Lipid Res 53: 1482-1492, 2012.
65. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, and Dagenais GR. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293: 1338-1347, 2005.
66. Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, Zhang M, Zhang Y, and An F. NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model. PLoS One 9: e104771, 2014.
67. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, and Abbate A. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 108: 19725-19730, 2011.
68. Mirza RE, Fang MM, Ennis WJ, and Koh TJ. Blocking IL-1beta induces a healing-associated wound macrophage phenotype and improves healing in type-2 diabetes. Diabetes 62: 2579-2587, 2013.
69. Mitra R, Nogee DP, Zechner JF, Yea K, Gierasch CM, Kovacs A, Medeiros DM, Kelly DP, and Duncan JG. The transcriptional coactivators, PGC-1alpha and beta, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol 52: 701-710, 2012.
70. Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, Potelle C, El Arid JM, Mouton S, Sebti Y, Duez H, Preau S, Remy-Jouet I, Zerimech F, Koussa M, Richard V, Neviere R, Edme JL, Lefebvre P, and Staels B. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130: 554-564, 2014.
71. Mullen TD and Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem 12: 340-363, 2012.
72. Muoio DM and Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 15: 595-605, 2012.
73. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, Kheterpal I, Zhang J, Covington JD, Bajpeyi S, Ravussin E, Kraus W, Koves TR, and Mynatt RL. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab 15: 764-777, 2012.
74. Murray AJ, Anderson RE, Watson GC, Radda GK, and Clarke K. Uncoupling proteins in human heart. Lancet 364: 1786-1788, 2004.
75. Nichols GA, Koro CE, Gullion CM, Ephross SA, and Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21: 51-57, 2005.
76. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, and Goldberg IJ. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49: 2101-2112, 2008.
77. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, and Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572, 2008.
78. Peterson LR, Saeed IM, McGill JB, Herrero P, Schechtman KB, Gunawardena R, Recklein CL, Coggan AR, DeMoss AJ, Dence CS, and Gropler RJ. Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. Obesity (Silver Spring) 20: 802-810, 2012.
79. Rindler PM, Crewe CL, Fernandes J, Kinter M, and Szweda LI. Redox regulation of insulin sensitivity due to enhanced fatty acid utilization in the mitochondria. Am J Physiol Heart Circ Physiol 305: H634-E643, 2013.
80. Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, and Gomez F. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol 166: 404-412, 2013.
81. Rutkowsky JM, Knotts TA, Ono-Moore KD, McCoin CS, Huang S, Schneider D, Singh S, Adams SH, and Hwang DH. Acylcarnitines activate pro-inflammatory signaling pathways. Am J Physiol Endocrinol Metab 306: E1378-E1387, 2014.
82. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N, and Kitakaze M. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 119: 2568-2577, 2009.
83. Schannwell CM, Schneppenheim M, Perings S, Plehn G, and Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98: 33-39, 2002.
84. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, and Kelly DP. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor {gamma} coactivator-1 (PGC-1) signaling. Circ Heart Fail 4: 474-482, 2011.
85. Schilling JD, Machkovech HM, Kim AH, Schwendener R, and Schaffer JE. Macrophages modulate cardiac function in lipotoxic cardiomyopathy. Am J Physiol Heart Circ Physiol 303: H1366-H1373, 2012.
86. Schilling JD and Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin 8: 619-631, 2012.
87. Schmitz FJ, Rosen P, and Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Horm Metab Res 27: 515-522, 1995.
88. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, and Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. Faseb J 18: 1692-1700, 2004.
89. Shen X, Zheng S, Metreveli NS, and Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55: 798-805, 2006.
90. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, Rentsendorj A, Vargas M, Guerrero C, Wang Y, Fitzgerald KA, Underhill DM, Town T, and Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36: 401-414, 2012.
91. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, and Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 120: 3443-3454, 2010.
92. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14: 49-57, 1989.
93. Styskal J, Van Remmen H, Richardson A, and Salmon AB. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med 52: 46-58, 2012.
94. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, and Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43: 720-729, 2007.
95. Tocchetti CG, Caceres V, Stanley BA, Xie C, Shi S, Watson WH, O'Rourke B, Spadari-Bratfisch RC, Cortassa S, Akar FG, Paolocci N, and Aon MA. GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes 61: 3094-3105, 2012.
96. van de Weijer T, Schrauwen-Hinderling VB, and Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 92: 10-18, 2011.
97. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, and Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17: 179-188, 2011.
98. Wang H, Sreenivasan U, Gong DW, O'Connell KA, Dabkowski ER, Hecker PA, Ionica N, Konig M, Mahurkar A, Sun Y, Stanley WC, and Sztalryd C. Cardiomyocytespecific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction. J Lipid Res 54: 953-965, 2013.
99. Wassmann S, Wassmann K, and Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 44: 381-386, 2004.
100. Weber KJ and Schilling JD. Lysosomes integrate metabolic-inflammatory crosstalk in primary macrophage inflammasome activation. J Biol Chem 289: 9158-9171, 2014.
101. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, and Ting JP. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408-415, 2011.
102. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, and Tschope C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49: 2507-2513, 2006.
103. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, and Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56: 1834-1841, 2007.
104. Wold LE, Ceylan-Isik AF, and Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 26: 908-917, 2005.
105. Wu SB, Wu YT, Wu TP, and Wei YH. Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochim Biophys Acta 1840: 1331-1344, 2014.
106. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, and Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100: 1208-1217, 2007.
107. Yuan Y, Jiao X, Lau WB, Wang Y, Christopher TA, Lopez BL, Ramachandrarao SP, Tao L, and Ma XL. Thioredoxin glycation: a novel posttranslational modification that inhibits its antioxidant and organ protective actions. Free Radic Biol Med 49: 332-338, 2010.
108. Yusuf S, Dagenais G, Pogue J, Bosch J, and Sleight P. Vitamin E supplementation and cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160, 2000.
109. Zhou R, Yazdi AS, Menu P, and Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225, 2011.